Challenges in the Development and Commercialization of Genome-Edited Crops: A Critical Review of Technical, Regulatory and Socio-Industrial Bottlenecks
Affiliations: 1 Center of Agricultural Biotechnology and Biochemistry, University of Agriculture, Faisalabad (CABB, UAF) 2 School of Biochemistry and Biotechnology, University of the Punjab Lahore (SBB, PU) 3 Department of Life Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan
Corresponding author: Zubair Ameen
Abstract
Since 2020, hundreds of proof-of-concept traits have been created using genome editing technologies such as the CRISPR/Cas nuclease, base editors and prime editors that can modify the genome of crops with high precision—many times without transgenes. Despite this technical maturity, few genome-edited crops have moved beyond lab demonstrations to market, such as high-oleic soybean, waxy corn and non-browning mushroom, demonstrating a chasm between the lab and the market. This review aims to identify and synthesise the peer-reviewed and policy literature to critically appraise the non-molecular bottlenecks to this transition. Despite progress in this area including GRF–GIF mediated regeneration and AI-assisted guide-RNA design, at the technical level, the deployment of these advances is being hindered by genotype-dependent regeneration, polyploidy genome complexity and the need for thorough off-target and transgene-free verification of new cultivars. Regulatory philosophies differ between product-based (United States, India, United Kingdom) and process-based (European Union), which creates a mix of trade friction, asynchrony in approvals and enforcement issues related to the analytical indistinguishability of SDN-1/SDN-2 edits and spontaneous mutations. A high number of patents block commercialization of CRISPR and the issue of Essentially Derived Variety has yet to be resolved and is focused on the perceived benefit rather than the process or naturalness of the product, all leading to concentration of market entry by well-resourced multinational companies. We define convergence towards outcome-based and risk-proportionate regulatory exemptions as most immediate steps towards harmonization, while calling attention to open-source licensing platforms and investment in delivery technologies for recalcitrant and orphan crops as priorities for equitable access globally. We believe that bringing to market the commercial potential of genome edited crops will necessitate an integrated multi-disciplinary programme of development, which must include both improvements in editing efficiencies and regulatory harmonisation and the development of an equitable regime for the governance of intellectual property, not just the former.
Keywords: CRISPR/Cas; genome editing; genome-edited crops; New Genomic Techniques (NGTs); regulatory harmonization; SDN classification; intellectual property; Essentially Derived Variety; consumer acceptance
Article Information
Declarations
Funding
No funding at all.
Conflict of interest
The authors have no conflicts of interest to declare.
Ethics approval
Not applicable
Informed consent
Not applicable. This study did not involve human participants or the collection of identifiable personal information.
Trial registration
Not applicable
Data availability
There are no new data sets created or analysed in the present study, and therefore, data sharing is not applicable.
Author contributions
Zubair Ameen: Conceptualization, methodology, literature search, formal analysis, writing—original draft preparation, writing—review and editing, project administration, and supervision. Hussain Ali Abdy: Literature analysis, data curation, visualization, and writing—review and editing. Muhammad Zeeshan: Literature search, validation, software and figure design, and writing—review and editing. All authors have read and approved the final version of the manuscript.
AI-use disclosure
The authors declare that no artificial intelligence tools were used in the generation, analysis, or writing of the core manuscript content.
Full Text
The complete peer-reviewed version of record is available as the JBSS article PDF.
Read Full Article PDFHow to Cite and Export
Zubair Ameen, Hussain Ali Abdy, Muhammad Zeeshan. Challenges in the Development and Commercialization of Genome-Edited Crops: A Critical Review of Technical, Regulatory and Socio-Industrial Bottlenecks. Journal of Biological and Sustainability Sciences. 2026;2(1):1-11. https://doi.org/10.5281/zenodo.22817951